SAN DIEGO, CA - (July 24, 1998) Privately held Structural Bioinformatics Inc. ("SBI") of San Diego, California announced today that Dean W. Goddette, Ph.D. has joined SBI as Vice President of Marketing and Sales. With over 15 years experience in research, sales and marketing, Dr. Goddette will have primary responsibility for worldwide marketing strategies for SBI's structural database products and services.

Structural Bioinformatics is a rapidly growing company that helps pharmaceutical companies accelerate drug discovery by making practical use of genomic data ultimately leading to the rapid identification of small molecule lead compounds. Dr. Goddette's scientific background in protein engineering and x-ray crystallography, combined with his experience in sales and marketing, will provide essential insight into the needs of a highly sophisticated customer base in the pharmaceutical industry. Edward T. Maggio, Chairman, President and CEO of SBI, said, "Dean's background contains the exact mix of both technical and business expertise that SBI has been seeking for the upcoming release of our first protein structure based proteomics and pharmacogenomics database products."

Dr. Goddette has a distinguished career in protein modeling and computational chemistry. Most recently he served as Senior Product Manager for Tripos' (TRPS) drug discovery product line before becoming their Central US and Canadian Sales Manager. Prior to joining Tripos, Dr. Goddette was Director of Life Sciences at Molecular Simulations Inc. (PCOP) where he managed their Quanta protein modeling product line. Earlier in his career, Dr. Goddette's research in protein engineering has led to numerous patents and publications.

Structural Bioinformatics has developed a supercomputational operating system making possible the immediate and practical use of genomic (gene sequence) data in a broad range of structure-based drug discovery and design processes leading to the rapid design and identification of small molecule lead compounds. SBI is building corporate partnerships with pharmaceutical companies, gene discovery companies, and combinatorial chemistry companies ranging from broad technology collaborations to assistance with specific drug targets or target groups. SBI has major corporate collaborations with Yamanouchi Pharmaceutical Co., Ltd., Biochem Pharma, Inc., and another undisclosed Japanese pharmaceutical company.